AgingResearch.NewsJoin free

KymaThera

CompanyUnited States

KymaThera develops one asset, preclinical (K-1728 in cancer). Mostly small molecule acting on PIK3CA; based in the United States.

1
Asset
Furthest stage
Preclinical
Raised
US$80m
1
Trial
1
Signal

Pipeline

1

  • K-1728

    Pan-mutant selective inhibitor of PI3Kα sparing wild-type PI3Kα

    Preclinical, Small molecule, PIK3CA, cancer, vascular malformations

Full company profiles: pipeline, trials, funding and people.

See Pro

In the full profile

  • Evidence behind the mechanisms1
  • Trials1
  • Funding rounds and grants1
  • Signals1
  • Similar companies6

Intelligence